Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
Status:
Completed
Trial end date:
2012-04-24
Target enrollment:
Participant gender:
Summary
This in an open-label, single dose, fixed sequence, two treatment period study enrolling 8
patients (to obtain 6 evaluable) with end stage renal disease (ESRD) receiving haemodialysis.
Patients will remain in the unit during each treatment period from admission to the
collection of the final PK sample. The doses of ezogabine/retigabine in the two treatment
periods will be separated by at least 7 days.